CN104606204A - Febrifuge for children - Google Patents
Febrifuge for children Download PDFInfo
- Publication number
- CN104606204A CN104606204A CN201510071108.4A CN201510071108A CN104606204A CN 104606204 A CN104606204 A CN 104606204A CN 201510071108 A CN201510071108 A CN 201510071108A CN 104606204 A CN104606204 A CN 104606204A
- Authority
- CN
- China
- Prior art keywords
- fever
- children
- parts
- dexamethasone
- dipyridamole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 27
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 25
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 25
- 229960002768 dipyridamole Drugs 0.000 claims abstract description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 abstract description 30
- 206010037660 Pyrexia Diseases 0.000 abstract description 29
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 28
- 239000002221 antipyretic Substances 0.000 abstract description 26
- 208000021760 high fever Diseases 0.000 abstract description 17
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000003266 anti-allergic effect Effects 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 230000000916 dilatatory effect Effects 0.000 abstract description 3
- 230000017525 heat dissipation Effects 0.000 abstract description 3
- 230000000703 anti-shock Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 12
- 206010067484 Adverse reaction Diseases 0.000 description 10
- 230000006838 adverse reaction Effects 0.000 description 10
- 230000036760 body temperature Effects 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 7
- 229940125716 antipyretic agent Drugs 0.000 description 7
- 201000005884 exanthem Diseases 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940016802 ibuprofen oral suspension Drugs 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 229940072651 tylenol Drugs 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- 241000202726 Bupleurum Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940090007 persantine Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 208000021754 continuous fever Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药技术领域,具体是涉及到一种儿童退烧药,由如下重量组分组成:地塞米松 0.5-3份,潘生丁8-25份,去痛片 50-150份,生理盐水 1万-2万份;本发明的潘生丁具有扩张血管的功能,血管扩张,血液流速增快,有利于散热;地塞米松具有抗炎、抗病毒、抗休克、防过敏的功效;去痛片可退热并缓解轻、中度疼痛,本发明的三种有效组分合并使用,协同发挥作用,且克服了各自的缺陷,高热不退者使用一到两次,即可退热,且能够达到持续退热的功效。The invention belongs to the technical field of medicine, and in particular relates to an antipyretic for children, which consists of the following components by weight: 0.5-3 parts of dexamethasone, 8-25 parts of dipyridamole, 50-150 parts of Qutong Tablets, and 10,000 parts of normal saline -20,000 copies; dipyridamole of the present invention has the function of dilating blood vessels, blood vessels dilate, and blood flow speed increases, which is beneficial to heat dissipation; dexamethasone has anti-inflammatory, anti-viral, anti-shock, and anti-allergic effects; Qutong Tablets can be withdrawn heat and relieve mild and moderate pain, the three effective components of the present invention are used in combination to play a synergistic role, and overcome their respective defects. Those with persistent high fever can reduce their fever after using it once or twice, and can achieve sustained Antipyretic effect.
Description
技术领域 technical field
本发明属于医药技术领域,具体是涉及到一种儿童退烧药。 The invention belongs to the technical field of medicine, and in particular relates to an antipyretic for children.
背景技术 Background technique
高热是儿童常见的疾病,常常不容易控制,且易发生反复性高热。一般用退烧药进行控制,退烧药的剂型主要有口服药、针剂、贴剂。 High fever is a common disease in children, often difficult to control, and prone to recurrent high fever. Generally, antipyretics are used for control, and the dosage forms of antipyretics mainly include oral medicines, injections, and patches.
(1)口服药:儿童常常难以咽下口服药。 (1) Oral medicine: Children often have difficulty swallowing oral medicine.
(2)针剂:儿童血管较细小,难以穿刺,且儿童好动,容易导致穿刺失败,造成淤血,给儿童带来痛苦。 (2) Injection: Children's blood vessels are small and difficult to puncture, and children are active, which may easily lead to puncture failure, cause congestion, and bring pain to children.
(3)贴剂:皮肤对贴剂的吸收较慢,降温缓慢,不能用于高热迅速降温。 (3) Patch: The skin absorbs the patch slowly and cools down slowly, so it cannot be used for rapid cooling of high fever.
退烧药是一种可以通过调节人体机能使人体体表血管扩张、进而借助于出汗等过程使散热增加,同时抑制寒战、使机体产热减少的药品。它能有效地控制发烧,使体温降低,但不能根本解除引起发热的原因。发烧是许多疾病共有的症状之一,治疗发烧不论病因病情地使用退烧药是不行的。退烧药有毒副作用。 Antipyretics are medicines that can dilate blood vessels on the human body surface by regulating human body functions, and then increase heat dissipation through processes such as sweating, while suppressing chills and reducing body heat production. It can effectively control fever and lower body temperature, but it cannot fundamentally eliminate the cause of fever. Fever is one of the common symptoms of many diseases. It is not acceptable to use antipyretics to treat fever regardless of the etiology and condition. Antipyretics have toxic side effects.
退烧药很常用,但其毒副作用也是常见的。诸如药疹、胃肠道反应、血液系统反应及对肝肾功能的损害等,尤其是当久用或过量使用此类药物时,毒副作用更加显著。 Antipyretics are commonly used, but their toxic side effects are also common. Such as drug eruption, gastrointestinal tract reaction, blood system reaction and damage to liver and kidney function, etc., especially when such drugs are used for a long time or excessively, the toxic and side effects are more significant.
目前市场上常见的儿科退烧药由以下几种: Common pediatric antipyretics currently on the market include the following:
1、对乙酰氨基酚,是一种安全的退热药,其退热效果与剂量成正比,但剂量过大会引起肝肾功能损害,因此,使用时应严格遵守剂量,不能过量。剂量为每公斤体重10~15毫克,4~6小时一次。代表药如泰诺林、小儿百服宁滴剂等。 1. Acetaminophen is a safe antipyretic drug. Its antipyretic effect is directly proportional to the dosage, but excessive dosage can cause damage to liver and kidney function. The dose is 10-15 mg per kg body weight, once every 4-6 hours. Representative drugs such as Tylenol, Xiaoerbaifuning drops and so on.
2、柴胡注射液:为从中药柴胡中提取的注射剂,该药退热作用较慢且弱,副作用少,但需注意,有过敏体质的孩子应慎用。 2. Bupleurum Injection: It is an injection extracted from the traditional Chinese medicine Bupleurum. The antipyretic effect of this medicine is slow and weak, and there are few side effects. However, it should be noted that children with allergies should use it with caution.
3、布洛芬:为非甾体类抗炎药,具有明显的解热镇痛作用,副作用少,本品可以代替肌肉注射退热药,适用于感染性疾病所致高热患儿使用。剂量为每公斤体重5~10毫克,每6~8小时一次。代表药为托恩口服溶液、小儿美林糖浆。 3. Ibuprofen: It is a non-steroidal anti-inflammatory drug, which has obvious antipyretic and analgesic effects, and has few side effects. This product can replace intramuscular injection of antipyretic drugs, and is suitable for children with high fever caused by infectious diseases. The dose is 5-10 mg per kg body weight, once every 6-8 hours. The representative medicines are Torn Oral Solution and Pediatric Merrill Syrup.
4、安痛定,又名复方氨基比林,是临床上最常用的一种退热药,但若短期内反复多次注射本品易致急性粒细胞缺乏症,有致命危险,对于某些患儿来说,本药有诱发急性溶血性贫血,皮疹等副作用,此外,如注射本品剂量过大会使孩子出汗过多,体温骤降,易引起虚脱,因此,复方氨基比林婴幼儿禁用,年长儿慎用。 4. Antongding, also known as compound aminopyrine, is the most commonly used antipyretic drug in clinical practice. However, repeated injections of this product in a short period of time can easily cause acute agranulocytosis, which is fatal. For some For children, this drug has side effects such as inducing acute hemolytic anemia and skin rash. In addition, if the dose of this product is injected too much, the child will sweat excessively, and the body temperature will drop suddenly, which will easily cause collapse. Disabled, use with caution in older children.
5、安乃近:主要副作用为肾毒性、胃肠道出血、严重皮疹,致死性粒细胞缺乏为其最严重副作用。目前有很多国家禁止使用或限制使用本品,但国内还有的地方医院还在使用,值得引起高度重视。 5. Analgin: The main side effects are nephrotoxicity, gastrointestinal bleeding, and severe skin rash, and fatal agranulocytosis is the most serious side effect. At present, many countries prohibit or restrict the use of this product, but some local hospitals in China still use it, which deserves great attention.
6、阿司匹林:这是一种历史悠久的退烧药,退热作用较强,但副作用大,目前在国内儿科趋于淘汰,使用时,应遵照医嘱,按时按量服用。 6. Aspirin: This is an antipyretic with a long history. It has a strong antipyretic effect, but it has a lot of side effects. At present, it is tending to be eliminated in domestic pediatrics.
7、中成药的退热药物。 7. Antipyretic drugs of Chinese patent medicines.
发明内容 Contents of the invention
本发明要解决的技术问题是提供一种儿童退烧药,其退烧作用快,毒副作用小,且能够达到持续退热的功效。 The technical problem to be solved by the present invention is to provide an antipyretic medicine for children, which has fast antipyretic effect, less toxic and side effects, and can achieve continuous antipyretic effect.
为解决上述技术问题,本发明的内容是由如下重量组分组成: In order to solve the problems of the technologies described above, content of the present invention is made up of following weight components:
地塞米松 0.5-3份, Dexamethasone 0.5-3 parts,
潘生丁8-25份, Persantine 8-25 parts,
去痛片 50-150份, Qu Pain Tablets 50-150 copies,
生理盐水 1万-2万份。 10,000-20,000 parts of normal saline.
优选的,所述儿童退烧药由如下重量组分组成: Preferably, the antipyretic for children consists of the following components by weight:
地塞米松 1-2份, 1-2 parts of dexamethasone,
潘生丁12.5-20份, Persantine 12.5-20 parts,
去痛片75-125份, 75-125 servings of Pain Relief Tablets,
生理盐水1万-1.5万份。 10,000-15,000 copies of normal saline.
最优选的,所述儿童退烧药由如下重量组分组成: Most preferably, the antipyretic for children consists of the following components by weight:
地塞米松1.5份, 1.5 parts of dexamethasone,
潘生丁16份, 16 parts of dipyridamole,
去痛片100份, 100 copies of Pain Relief Tablets,
生理盐水1万份。 10,000 parts of normal saline.
本发明的地塞米松,又叫德沙美松、氟甲强的松龙是抗炎、抗过敏药物。主要作为危重疾病的急救用药和各类炎症的治疗。药理作用主要是抗炎、抗毒、抗过敏、抗风湿,临床使用较广泛。用于退烧时,能够抑制致热源的释放,降低体温中枢的敏感性,极易自消化道吸收。其具有以下功能:抗炎作用和免疫抑制作用。 The dexamethasone of the present invention, also known as Dexamethasone and Flumeprednisolone, are anti-inflammatory and anti-allergic drugs. It is mainly used as emergency medicine for critical illness and treatment of various inflammations. The pharmacological effects are mainly anti-inflammatory, anti-toxic, anti-allergic, anti-rheumatic, and are widely used clinically. When used to reduce fever, it can inhibit the release of pyrogens, reduce the sensitivity of the body temperature center, and is easily absorbed from the digestive tract. It has the following functions: anti-inflammatory and immunosuppressive effects.
地塞米松的常见不良反应有以下几类: Common side effects of dexamethasone include the following:
1.长程使用可引起以下副作用:医源性库欣综合征面容和体态、体重增加、下肢浮肿、紫纹、易出血倾向、创口愈合不良、痤疮、月经紊乱、肱或股骨头缺血性坏死、骨质疏松及骨折、肌无力、肌萎缩、低血钾综合征、胃肠道刺激、胰腺炎、消化性溃疡或穿孔,儿童生长受到抑制、青光眼、白内障、良性颅内压升高综合征、糖耐量减退和糖尿病加重。 1. Long-term use can cause the following side effects: iatrogenic Cushing syndrome appearance and posture, weight gain, lower extremity edema, purple streaks, easy bleeding tendency, poor wound healing, acne, menstrual disorders, avascular necrosis of the humerus or femoral head, bone osteoporosis and fractures, muscle weakness, muscle atrophy, hypokalemia syndrome, gastrointestinal irritation, pancreatitis, peptic ulcer or perforation, growth inhibition in children, glaucoma, cataract, benign intracranial hypertension syndrome, diabetes Impaired tolerance and exacerbation of diabetes.
2.患者可出现精神症状:欣快感、激动、谵妄、不安、定向力障碍,也可表现为抑制。精神症状由易发生与患慢性消耗性疾病的人及以往有过精神不正常者。 2. Patients may present with psychiatric symptoms: euphoria, agitation, delirium, restlessness, disorientation, and depression. Mental symptoms are prone to occur with people suffering from chronic wasting diseases and those who have had mental disorders in the past.
3.并发感染为肾上腺皮质激素的主要不良反应。 3. Concurrent infection is the main adverse reaction of adrenocortical hormone.
4.糖皮质激素停药综合征。 4. Glucocorticoid withdrawal syndrome.
地塞米松用于高热降温,但有并发症,如降低身体免疫功能,阻碍抗体形成,使某些致病菌趁机生长繁殖,引起二次感染或某些炎性疾病等,体温骤然下降并大量出汗,容易引起虚脱。 Dexamethasone is used to cool down high fever, but there are complications, such as reducing the body's immune function, hindering the formation of antibodies, causing some pathogenic bacteria to take advantage of the opportunity to grow and reproduce, causing secondary infections or certain inflammatory diseases, etc. The body temperature suddenly drops and a large number of Sweating can easily cause collapse.
本发明的潘生丁,别名双嘧啶胺醇,双嘧达莫(Dipyridamole),双嘧达莫哌醇定,系非硝酸酯类冠状动脉扩张剂,具有扩张冠状血管、促进侧支循环形成和轻度抗凝作用。潘生丁具有抗病毒的作用,通过抑制二氧嘧啶核苷通过细胞膜进入FL细胞,并能选择性抑制病毒PNA的合成,从而能完全抑制病毒特异的增殖过程。其常见副作用为乏力、头痛、眩晕、昏厥、呕吐、腹泻、脸红、皮疹、瘙痒和胃肠道不适等,在临床上通常认为本品不能与其他药物混合注射。 Dipyridamole of the present invention, alias dipyridamole, dipyridamole (Dipyridamole), dipyridamole, is a non-nitrate coronary artery dilator, which has the functions of dilating coronary blood vessels, promoting the formation of collateral circulation and mild Anticoagulant effect. Dipyridamole has an antiviral effect, by inhibiting the entry of dioxypyrimidine nucleosides into FL cells through the cell membrane, and selectively inhibiting the synthesis of viral PNA, thereby completely inhibiting the virus-specific proliferation process. Its common side effects are fatigue, headache, dizziness, fainting, vomiting, diarrhea, flushing, rash, itching and gastrointestinal discomfort, etc. It is usually considered that this product cannot be mixed with other drugs for injection in clinical practice.
潘生丁一般不用于退烧,用于退烧也仅可降温,但是伴有并发症,如乏力、头痛、眩晕、昏厥、胃肠道不适、扁桃体炎、支气管炎、支气管肺炎等。 Dipyridamole is generally not used for reducing fever, and it can only reduce temperature when used for reducing fever, but it is accompanied by complications, such as fatigue, headache, dizziness, fainting, gastrointestinal discomfort, tonsillitis, bronchitis, bronchopneumonia, etc.
本发明的去痛片为复方制剂,其组份为:每片由氨基比林150mg、非那西丁150mg、咖啡因50mg、苯巴比妥15mg组成。去痛片需要避免与其它非甾体抗炎药,包括选择性COX-2抑制剂合并用药,因为在使用所有非甾体抗炎药治疗过程中的任何时候,都可能出现胃肠道出血、溃疡和穿孔的不良反应,其风险可能是致命的。 The Qutong tablet of the present invention is a compound preparation, and its components are as follows: each tablet is composed of 150 mg of aminopyrine, 150 mg of phenacetin, 50 mg of caffeine and 15 mg of phenobarbital. Qutong tablets need to be avoided in combination with other non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors, because gastrointestinal bleeding, Adverse effects of ulceration and perforation, the risk of which can be fatal.
去痛片可用于高热降温,同时又有镇静功效,利于患儿休息。其一般不用于退烧,用于退烧时会造成消化系统副反应,如消化不良、恶心呕吐,皮肤反应如皮疹、瘙痒等。 Qutong tablets can be used to cool down high fever, and at the same time have a sedative effect, which is beneficial for children to rest. It is generally not used to reduce fever. When it is used to reduce fever, it will cause side effects of the digestive system, such as indigestion, nausea and vomiting, and skin reactions such as rash and itching.
本发明的所述生理盐水为重量浓度为0.85~0.9%的氯化钠溶液。 The physiological saline in the present invention is a sodium chloride solution with a weight concentration of 0.85-0.9%.
本发明的有益效果是,本发明的潘生丁具有扩张血管的功能,血管扩张,血液流速增快,有利于散热;地塞米松具有抗炎、抗病毒、抗休克、防过敏的功效;去痛片可退热并缓解轻、中度疼痛,具有镇静功效。三种有效组分合并使用,协同发挥作用,且克服了各自的缺陷,高热不退者使用一到两次,即可退热,且能够达到持续退热的功效。 The beneficial effects of the present invention are that dipyridamole of the present invention has the function of dilating blood vessels, blood vessels dilate, and blood flow speed increases, which is beneficial to heat dissipation; dexamethasone has anti-inflammatory, anti-viral, anti-shock, and anti-allergic effects; It can reduce fever and relieve mild and moderate pain, and has a sedative effect. The three effective components are used in combination to play a synergistic role, and overcome their respective defects. People with persistent high fever can reduce fever after using it once or twice, and can achieve the effect of continuous fever reduction.
具体实施方式 Detailed ways
实施例1 Example 1
本发明的儿童退烧药由地塞米松1.5mg,潘生丁16mg,去痛片100mg,生理盐水10ml组成。制备方法为,将地塞米松、潘生丁和去痛片研磨粉碎,放入生理盐水中溶解得到。 The antipyretic medicine for children of the present invention is composed of 1.5 mg of dexamethasone, 16 mg of dipyridamole, 100 mg of Qutong tablets and 10 ml of normal saline. The preparation method is that the dexamethasone, dipyridamole and Qutong tablets are ground and pulverized, and dissolved in physiological saline.
实施例2 Example 2
本发明的儿童退烧药由地塞米松1mg,潘生丁20mg,去痛片75mg,生理盐水15ml组成。制备方法同实施例1。 The antipyretic medicine for children of the present invention is composed of 1 mg of dexamethasone, 20 mg of dipyridamole, 75 mg of Qutong tablets and 15 ml of normal saline. The preparation method is the same as in Example 1.
实施例3 Example 3
本发明的儿童退烧药由地塞米松2mg,潘生丁12.5mg,去痛片125mg,生理盐水10ml组成。制备方法同实施例1。 The antipyretic medicine for children of the present invention is composed of 2 mg of dexamethasone, 12.5 mg of dipyridamole, 125 mg of Qutong tablets and 10 ml of normal saline. The preparation method is the same as in Example 1.
实施例4 Example 4
本发明的儿童退烧药由地塞米松0.5mg,潘生丁25mg,去痛片50mg,生理盐水10ml组成。制备方法同实施例1。 The antipyretic medicine for children of the present invention is composed of 0.5 mg of dexamethasone, 25 mg of dipyridamole, 50 mg of Qutong tablets and 10 ml of normal saline. The preparation method is the same as in Example 1.
实施例5 Example 5
本发明的儿童退烧药由地塞米松3mg,潘生丁8mg,去痛片150mg,生理盐水20ml组成。制备方法同实施例1。 The antipyretic medicine for children of the present invention is composed of 3 mg of dexamethasone, 8 mg of dipyridamole, 150 mg of Qutong tablets and 20 ml of normal saline. The preparation method is the same as in Example 1.
实施例6 Example 6
使用方法为:使用注射器将实施例1-5任一项得到的儿童退烧药经过儿童肛门导入直肠内。 The method of use is as follows: use a syringe to introduce the antipyretic medicine for children obtained in any one of Examples 1-5 into the rectum through the anus of the child.
实施例7 Example 7
使用方法为:利用一次性使用肛门管将实施例1-5任一项得到的儿童退烧药经过儿童肛门导入直肠内。 The method of use is as follows: the children's antipyretic medicine obtained in any one of Examples 1-5 is introduced into the rectum through the children's anus by using a disposable anal canal.
实施例8 Example 8
效果说明 Effect description
对78例高热者,于2015年1月在湖南中医药大学第二附属医院门诊部按照实施例7的方法使用实施例1制备的儿童退烧药,发现使用后有75例高热儿童恢复正常,降温率达96.15%。高热者主要表现为:体温处于39.1-40℃之间,高热不退或者高热反复;高热儿童恢复正常的主要表征为:体温处于36.5-37.5℃之间,不会出现高热反跳,且1次用药后降温持续时间约为18-24小时。若此后患儿体温处于36.5-37.5℃之间,说明退烧成功,若18-24小时后出现高热反跳,则说明退烧失败。需要考虑其他原因所致发热(如支原体感染等),需要通过血培养确定病因学的检查。 For 78 cases of high fever patients, in January 2015, in the outpatient department of the Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, the antipyretic medicine for children prepared in Example 1 was used according to the method of Example 7, and it was found that 75 cases of high fever children returned to normal after use. The rate reached 96.15%. The main manifestations of high fever are: body temperature is between 39.1-40°C, high fever persists or high fever is repeated; the main symptoms of high fever children returning to normal are: body temperature is between 36.5-37.5°C, there will be no rebound of high fever, and once The duration of cooling after administration is about 18-24 hours. If the child's body temperature is between 36.5-37.5 ℃, it means that the fever has been successfully reduced. If the high fever rebounds after 18-24 hours, it means that the fever has failed. Fever due to other causes (such as mycoplasma infection, etc.) needs to be considered, and blood cultures should be used to determine the etiology.
实施例9 Example 9
对比试验分析 Comparative test analysis
设计对比试验,即地塞米松、潘生丁、去痛片、泰诺林及布洛芬口服混悬液单独用药,以及本发明实施例1药物对儿童发烧进行退烧处理,进行对比分析,观察其疗效,观察患儿就诊第一次用药后对患儿退烧时间、退烧持续时间,及整个治疗周期的退烧结果、不良反应。具体结果见表1。 Design comparative test, namely dexamethasone, dipyridamole, Qutong Tablets, Tylenol and ibuprofen oral suspension are used alone, and the medicine of Example 1 of the present invention is used to reduce fever in children, carry out comparative analysis, and observe its curative effect , to observe the fever-reducing time and duration of the children's fever after the first medication, and the fever-reducing results and adverse reactions of the entire treatment cycle. The specific results are shown in Table 1.
表1 不同药物对高热患者退烧的影响表 Table 1 The effect of different drugs on fever reduction in patients with high fever
地塞米松、潘生丁、去痛片的用量按照其用于退烧的常见用量来使用。其中地塞米松的用量为2mg地塞米松溶于10ml生理盐水;潘生丁的用量为20mg溶于10ml生理盐水;去痛片(购于广东华南药业集团有限公司)、泰诺林(上海强生制药有限公司)、布洛芬口服混悬液(天大药业(珠海)有限公司)的用法按照其说明书进行。 The dosages of dexamethasone, dipyridamole, and Qutong tablets are used according to their usual dosages for reducing fever. Among them, the dosage of dexamethasone is 2mg dexamethasone dissolved in 10ml normal saline; the dosage of dipyridamole is 20mg dissolved in 10ml normal saline; Co., Ltd.), ibuprofen oral suspension (Tianda Pharmaceutical (Zhuhai) Co., Ltd.) according to its instructions.
退烧成功、退烧失败的表征见实施例8的说明。 Refer to the description of Example 8 for the characterization of successful and failed fever reduction.
地塞米松的2例不良反应的表征为,体温骤然下降并大量出汗,引起虚脱(心跳加快、呼吸急促、气短、胸闷、昏厥)。且有恶心、呕吐、反酸、食欲不振现象。 The 2 cases of adverse reactions of dexamethasone were characterized by a sudden drop in body temperature and profuse sweating, causing collapse (rapid heartbeat, shortness of breath, shortness of breath, chest tightness, fainting). And nausea, vomiting, acid reflux, loss of appetite phenomenon.
潘生丁的3例不良反应的表征为乏力、头痛、眩晕、昏厥、胃肠道不适等,其中1例还伴有扁桃体炎,1例伴有支气管炎。 The adverse reactions of dipyridamole in 3 cases were characterized by fatigue, headache, dizziness, fainting, and gastrointestinal discomfort, among which 1 case was accompanied by tonsillitis and 1 case was accompanied by bronchitis.
去痛片的2例不良反应的表征为消化不良、恶心呕吐,1例伴有皮疹、瘙痒。 Two cases of adverse reactions of Qutong Tablets were characterized by indigestion, nausea and vomiting, and one case was accompanied by rash and itching.
泰诺林的不良反应的表征为皮疹。 Tylenol adverse reactions are characterized by rash.
布洛芬口服混悬液的不良反应的表征为消化不良和皮疹。 Adverse reactions of ibuprofen oral suspension are characterized by dyspepsia and rash.
从表1中数据可以看出,相比应用地塞米松、潘生丁和去痛片对儿童进行退烧,应用本发明实施例1的药物对儿童进行退烧后,退烧时间短,持续时间长,退烧成功的概率更大,而且出现不良反应的概率更小。其卡方值和p值说明各药物退烧成功的概率有明显差别,出现不良反应的概率也有明显差别。即使相对于应用泰诺林及布洛芬口服混悬液对儿童进行退烧,本发明药物对儿童退烧的成功率也高,不良反应更小。 As can be seen from the data in Table 1, compared with the use of dexamethasone, dipyridamole and Qutong Tablets to reduce fever in children, after the medicine of Example 1 of the present invention is used to reduce fever in children, the fever reduction time is short, the duration is long, and the fever reduction is successful. The probability is higher, and the probability of adverse reactions is smaller. The chi-square value and p-value indicate that there is a significant difference in the probability of successful fever reduction of each drug, and there is also a significant difference in the probability of adverse reactions. Even compared with the use of Tylenol and ibuprofen oral suspension to reduce fever in children, the medicine of the present invention has a high success rate in reducing fever in children and has less adverse reactions.
所属领域的普通技术人员应当理解:以上所述仅为本发明的具体实施例而已,并不用于限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。 Those of ordinary skill in the art should understand that: the above descriptions are only specific embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, and improvements made within the spirit and principles of the present invention etc., should be included within the protection scope of the present invention.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071108.4A CN104606204A (en) | 2015-02-11 | 2015-02-11 | Febrifuge for children |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071108.4A CN104606204A (en) | 2015-02-11 | 2015-02-11 | Febrifuge for children |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104606204A true CN104606204A (en) | 2015-05-13 |
Family
ID=53141025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510071108.4A Pending CN104606204A (en) | 2015-02-11 | 2015-02-11 | Febrifuge for children |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104606204A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727642A (en) * | 2016-12-17 | 2017-05-31 | 郑州郑先医药科技有限公司 | A kind of children's antipyretic |
CN107773564A (en) * | 2016-08-26 | 2018-03-09 | 康普药业股份有限公司 | A kind of pharmaceutical composition of antipyretic-antalgic |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1586484A (en) * | 2004-07-12 | 2005-03-02 | 北京瑞伊人科技发展有限公司 | Dipyridamole soft capsule preparation and its preparing method |
-
2015
- 2015-02-11 CN CN201510071108.4A patent/CN104606204A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1586484A (en) * | 2004-07-12 | 2005-03-02 | 北京瑞伊人科技发展有限公司 | Dipyridamole soft capsule preparation and its preparing method |
Non-Patent Citations (2)
Title |
---|
侯美玉: "《感冒发汗能用止痛片吗?》", 《家庭医学》 * |
王晓英: "《地塞米松退热时不同给药方式疗效观察》", 《包头医学院学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107773564A (en) * | 2016-08-26 | 2018-03-09 | 康普药业股份有限公司 | A kind of pharmaceutical composition of antipyretic-antalgic |
CN106727642A (en) * | 2016-12-17 | 2017-05-31 | 郑州郑先医药科技有限公司 | A kind of children's antipyretic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Batchelor et al. | Formulations for children: problems and solutions | |
US10206919B2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
JPH04504579A (en) | Treatment of symptoms and diseases | |
JP2022050545A (en) | Methods and compositions for treating sepsis | |
US20200101067A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
Auyeung et al. | Successful treatment of Stevens–Johnson syndrome with cyclosporine and corticosteroid | |
CN104606204A (en) | Febrifuge for children | |
Peters et al. | Hyperosmolar therapy for the treatment of cerebral edema | |
CN111803488B (en) | Application of atractylenolide II in preparation of anti-renal fibrosis medicine and anti-renal fibrosis medicine | |
CN101978983A (en) | Chinese medicinal composition for treating acute upper respiratory infection and preparation method thereof | |
CN102198123B (en) | Prescription and preparation method of ibuprofen miniature enema | |
CN113750205A (en) | Traditional Chinese medicine composition for relieving and/or treating female reproductive system diseases | |
CN109966291A (en) | Application of compound SB216763 in the preparation of medicine for preventing and/or treating cerebrovascular disease and its pharmaceutical composition | |
CN113425723B (en) | Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis | |
CN106902121A (en) | Application of the ticagrelor in anaphy lactoid purpura nephritis adjuvant therapy medicaments | |
CN117137897B (en) | Application of Sofadone in Preparing Medications for Preventing/Treating Psoriasis | |
CN103463193B (en) | A kind of Chinese medicine composition for the treatment of gynaecologic metrorrhagia | |
RU2611383C2 (en) | Combined preparation for elimination of symptoms and treating acute respiratory viral infections and influenza | |
CN102204883B (en) | Prescription and preparation method of promethazine hydrochloride miniature enema | |
Thakurdesai et al. | S3542 Is It Safe to Take Your Dog’s Medication? A Case of Severe Drug-Induced Liver Injury Due to Self-Administration of Fenbendazole | |
Chen et al. | Effects of Damage Control Resuscitation Combined with Alanyl Glutamine on Complications and Survival in Sufferers with Severe Multiple Trauma. | |
CN110840869A (en) | The application of metformin in endometriosis drugs | |
Doggrell | Introduction to pharmacology, and routes of drugs administration and absorption | |
Lin et al. | Common Medicines Used after the Replantation of Amputated Fingers | |
WO2022204397A1 (en) | Treatment of long haulers syndrome with niclosamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150513 |
|
RJ01 | Rejection of invention patent application after publication |